End-of-day quote
OTC Markets
03:30:00 31/05/2024 am IST
|
5-day change
|
1st Jan Change
|
0.045
USD
|
-.--%
|
|
+76.47%
|
+126.13%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
---|
Capitalization
1 |
716.3
|
250.6
|
21.79
|
Enterprise Value (EV)
1 |
593
|
176.8
|
-14.44
|
P/E ratio
|
-3.1
x
|
-3.58
x
|
-0.27
x
|
Yield
|
-
|
-
|
-
|
Capitalization / Revenue
|
34.1
x
|
9.25
x
|
1.01
x
|
EV / Revenue
|
28.2
x
|
6.53
x
|
-0.67
x
|
EV / EBITDA
|
-11.9
x
|
-2.62
x
|
0.19
x
|
EV / FCF
|
-4,44,64,631
x
|
-46,04,375
x
|
4,30,068
x
|
FCF Yield
|
-0%
|
-0%
|
0%
|
Price to Book
|
5.65
x
|
2.03
x
|
0.38
x
|
Nbr of stocks (in thousands)
|
24,717
|
28,067
|
29,451
|
Reference price
2 |
28.98
|
8.930
|
0.7400
|
Announcement Date
|
18/03/21
|
16/03/22
|
22/03/23
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
12.67
|
20.11
|
21
|
27.1
|
21.48
|
EBITDA
1 |
-19.34
|
-32.88
|
-49.72
|
-67.56
|
-74.32
|
EBIT
1 |
-20.4
|
-34.26
|
-51.06
|
-68.77
|
-75.82
|
Operating Margin
|
-161.05%
|
-170.4%
|
-243.16%
|
-253.78%
|
-353.04%
|
Earnings before Tax (EBT)
1 |
-20.23
|
-32.2
|
-50.52
|
-68.74
|
-79.46
|
Net income
1 |
-20.23
|
-32.2
|
-50.52
|
-68.74
|
-79.46
|
Net margin
|
-159.71%
|
-160.14%
|
-240.6%
|
-253.68%
|
-369.98%
|
EPS
2 |
-13.43
|
-19.89
|
-9.352
|
-2.493
|
-2.758
|
Free Cash Flow
|
-
|
-11.25
|
-13.34
|
-38.4
|
-33.59
|
FCF margin
|
-
|
-55.93%
|
-63.52%
|
-141.71%
|
-156.38%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
09/10/20
|
09/10/20
|
18/03/21
|
16/03/22
|
22/03/23
|
Fiscal Period: December |
2021 Q2
|
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
---|
Net sales
1 |
4.539
|
4.755
|
12.35
|
2.869
|
3.215
|
3.452
|
11.94
|
-
|
0.178
|
-
|
EBITDA
|
-18.76
|
-22.16
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-19.08
|
-22.46
|
-11.83
|
-21.05
|
-22.5
|
-23.1
|
-9.17
|
-18.26
|
-17.11
|
-23.8
|
Operating Margin
|
-420.27%
|
-472.26%
|
-95.8%
|
-733.81%
|
-699.94%
|
-669.12%
|
-76.78%
|
-
|
-9,611.24%
|
-
|
Earnings before Tax (EBT)
1 |
-19.07
|
-22.45
|
-11.82
|
-21.04
|
-22.24
|
-22.64
|
-13.55
|
-17.69
|
-16.77
|
-23.64
|
Net income
1 |
-19.07
|
-22.45
|
-11.82
|
-21.04
|
-22.24
|
-22.64
|
-13.55
|
-17.69
|
-16.77
|
-23.64
|
Net margin
|
-420.14%
|
-472.13%
|
-95.72%
|
-733.29%
|
-691.63%
|
-655.94%
|
-113.43%
|
-
|
-9,421.35%
|
-
|
EPS
2 |
-6.800
|
-8.000
|
-4.100
|
-7.500
|
-7.800
|
-7.700
|
-4.600
|
-6.000
|
-0.5700
|
-0.8000
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
04/08/21
|
10/11/21
|
16/03/22
|
10/05/22
|
04/08/22
|
09/11/22
|
22/03/23
|
10/05/23
|
10/08/23
|
08/11/23
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
107
|
56
|
123
|
73.8
|
36.2
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-11.2
|
-13.3
|
-38.4
|
-33.6
|
ROE (net income / shareholders' equity)
|
-
|
-53%
|
-54.4%
|
-54.7%
|
-87.7%
|
ROA (Net income/ Total Assets)
|
-
|
-16%
|
-16.6%
|
-18.8%
|
-29.1%
|
Assets
1 |
-
|
201.4
|
303.6
|
365.7
|
273.4
|
Book Value Per Share
2 |
-27.10
|
-44.60
|
5.130
|
4.410
|
1.940
|
Cash Flow per Share
2 |
37.10
|
23.80
|
6.870
|
5.100
|
2.160
|
Capex
1 |
1.31
|
2.17
|
1.18
|
0.61
|
0.52
|
Capex / Sales
|
10.3%
|
10.78%
|
5.61%
|
2.26%
|
2.43%
|
Announcement Date
|
09/10/20
|
09/10/20
|
18/03/21
|
16/03/22
|
22/03/23
|
|
1st Jan change
|
Capi.
|
---|
| +126.13% | 13.27L | | +43.36% | 5.46TCr | | -5.31% | 3.99TCr | | +37.52% | 3.88TCr | | +14.75% | 2.69TCr | | -12.56% | 2.62TCr | | -22.45% | 1.88TCr | | +25.12% | 1.22TCr | | +0.04% | 1.22TCr | | +26.04% | 1.19TCr |
Other Biotechnology & Medical Research
|